[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-st-elevation-myocardial-infarction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-st-elevation-myocardial-infarction":223},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,41,74,103,145,169,196],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100519206","early-discharge-pathway-registry-100519206",false,"NCT06040528","Early Discharge Pathway Registry","Barts Early Post-Acute Myocardial Infarction Discharge Registry","Inclusion Criteria:\n\nInformed consent will not be sought for, as patients are automatically included onto a database that we will use for research purposes. No children will be included in this study. Vulnerable adults or those unable to give consent will be included in the study as well if they are referred to the Interventional Cardiology team.\n\nBoth male and female patients ≥16 years of age will be included\n\nAll patients will have been admitted to BHC with acute coronary syndrome.\n\nExclusion Criteria:\n\nPatients \\\u003C16 years will not be included in this study.","ALL","16 Years",{"count":19,"type":20},20000,"ESTIMATED","12 Months","OBSERVATIONAL","Despite the year-on-year decrease, coronary artery disease (CAD) still remains one of the leading causes of mortality worldwide. With advances in technology and our understanding of cardiac disease, we can now treat CAD using minimally invasive interventional techniques. This has revolutionised treatment for and improved the lives of many patients with CAD. Although trials have assessed various therapeutic strategies in various populations, real-world evidence of intervention and medical treatment among patients with CAD is increasingly recognised as an important part of providing safety and efficacy data and improving the care we provide.\n\nRegional heart attack services have improved clinical outcomes following ST-segment elevation myocardial infarction (STEMI) by facilitating early reperfusion by primary percutaneous coronary intervention (PCI). Early discharge after primary PCI is welcomed by patients and increases the efficiency of health care.\n\nThis data will add to that literature by assessing the characteristics and outcomes of patients with CAD, concentrating on those who are discharged via the early discharge pathway. It will also identify and characterise predictors of outcomes, and improve risk stratification and diagnostic evaluation.",[25,26,27],"Myocardial Infarction","ST Elevation Myocardial Infarction","Non-ST Elevation Myocardial Infarction","RECRUITING","2026-02-26",{"date":31,"type":32},"2026-02-27","ACTUAL",{"date":34,"type":32},"2023-11-11",{"date":36,"type":20},"2026-12-31",{"name":38,"class":39},"Queen Mary University of London","OTHER",2,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100499659","complete-revascularization-versus-culprit-lesion-only-pci-in-nstemi-100499659","NCT05786131","Complete Revascularization Versus Culprit Lesion Only PCI in NSTEMI","Complete Revascularization Versus Culprit Lesion Only PCI in NSTEMI (-COMPLETE-NSTEMI-)","CompleteNSTEMI","Inclusion Criteria:\n\n* NSTEMI as suggested by high-sensitivity troponin algorithms\n* Multivessel coronary artery disease\n* Identifiable culprit lesion\n* Informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Cardiogenic shock\n* Sustained ventricular tachycardia (VT) or ventricular fibrillation (VF)\n* Contraindication for coronary revascularization\n* Prior coronary artery bypass graft\n* Indication for coronary artery bypass graft surgery\n* Non-culprit lesion located in the left main coronary artery\n* Co-morbidity with life expectancy less than 6 months\n* Type 2 myocardial infarction\n* Pregnancy and breast feeding period","18 Years",{"count":51,"type":20},3390,"INTERVENTIONAL",[54],"NA","Prospective, randomized, controlled, multicenter, open-label trial to study whether multivessel percutaneous coronary intervention (PCI) is superior over culprit-lesion only PCI in patients with non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel coronary artery disease.",[57,58],"Non-ST-elevation Myocardial Infarction","Multivessel Coronary Artery Disease",[60,61,62,63],"NSTEMI","Multivessel coronary artery disease","culprit-lesion only PCI","multivessel percutaneous coronary intervention","2025-01-15",{"date":66,"type":32},"2025-01-16",{"date":68,"type":32},"2023-10-27",{"date":70,"type":20},"2027-07-31",{"name":72,"class":39},"Leipzig Heart Science gGmbH",58,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":52,"phases":85,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":40},"100501723","ivus-versus-ffr-for-non-infarct-related-artery-lesions-in-patients-with-multivessel-disease-and-acute-mi-100501723","NCT05812963","IVUS Versus FFR for Non-infarct Related Artery Lesions in Patients With Multivessel Disease and Acute MI","Randomized Controlled Trial of Intravascular Ultrasound Versus Fractional Flow Reserve for Non-infarct Related Artery Lesions in Patients With Multivessel Disease and Acute Myocardial Infarction","FRAME-AMI2","Inclusion Criteria:\n\n* Subject must be at least 19 years of age\n* Acute ST-segment elevation myocardial infarction (STEMI)\n\n  \\*STEMI: ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle-branch block\n* Acute non-ST-segment elevation myocardial infarction (NSTEMI)\n\n  \\*NSTEMI: NSTEMI is defined as a combination of criteria with mandated elevation of a cardiac biomarker, preferably high-sensitive cardiac troponin with at least one value above 99th percentile of the upper reference limit and at least one of the following:\n  1. Symptoms of ischemia.\n  2. New or presumed new significant ST-T wave changes\n  3. Development of pathological Q waves on electrocardiography.\n  4. Imaging evidence of new or presumed new loss of viable myocardium or regional wall motion abnormality.\n  5. Intracoronary thrombus detected on angiography.\n* Successful primary percutaneous coronary intervention (PCI) in \\\u003C 12 h after the onset of symptoms for STEMI patients (In case of NSTEMI, PCI should be performed within 72 hours of symptom onset)\n* Multivessel disease (at least one stenosis of \\>50% in a non-IRA ≥2.25 mm by visual estimation)\n* Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic evaluation and PCI and he\u002Fshe or his\u002Fher legally authorized representative provides written informed consent prior to any study related procedure.\n\nExclusion Criteria:\n\n* Non-IRA stenosis not amenable for PCI treatment by operators' decision\n* Cardiogenic shock (Killip class IV) already at presentation or the completion of IRA PCI\n* Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus\n* Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)\n* Pregnancy or breast feeding\n* Non-cardiac co-morbid conditions are present with life expectancy \\\u003C2 year or that may result in protocol non-compliance (per site investigator's medical judgment)\n* Other primary valvular disease with severe degree: severe mitral regurgitation, mitral stenosis, severe aortic regurgitation, or aortic stenosis\n* Unwillingness or inability to comply with the procedures described in this protocol.","19 Years",{"count":84,"type":20},1400,[54],"The aim of the study is to compare clinical outcomes between intravascular ultrasound (IVUS)-guided treatment decision versus fractional flow reserve (FFR)-guided treatment decision for non-infarct related artery stenosis in patients with acute myocardial infarction (AMI) and multivessel disease.",[26,27],[89,90,91,92,93,27],"ST-segment elevation MI","Fractional flow reserve","intravascular ultrasound","Multivessel disease","Complete revascularization","2024-10-22",{"date":96,"type":32},"2024-10-24",{"date":98,"type":32},"2023-09-18",{"date":100,"type":20},"2029-12-31",{"name":102,"class":39},"Samsung Medical Center",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":144},"100559630","cardiac-mri-prior-to-invasive-coronary-angiography-in-patients-with-suspected-non-st-elevation-myocardial-infarction-100559630","NCT06566625","Cardiac MRI Prior to Invasive Coronary Angiography in Patients With Suspected Non-ST-Elevation Myocardial Infarction","The Karolinska Pilot Study for Cardiac Magnetic Resonance Imaging Prior to Invasive Coronary Angiography in Patients With Suspected Non-ST-Elevation Myocardial Infarction","KaPSICA-CMR","Inclusion Criteria:\n\n* ≥18 years of age Suspected NSTEMI (signs and symptoms suggest of ACS with initial ECG showing no ST-elevation)\n* Planned ICA where CMR can be performed without delaying ICA\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Contraindications for CMR examination with gadolinium contrast (claustrophobia, eGFR \\\u003C30ml\u002Fmin\u002F1.73m2, contrast allergy, and non-MRI compatible implants)\n* Arrythmias which hinder CMR examination\n* Previous CABG\n* Hemodynamic instability\n* Myocardial infarction \\\u003C6 months prior to inclusion",{"count":112,"type":20},150,"Patients with a suspected myocardial infarction are subdivided into ST-elevation and non-ST-elevation myocardial infarctions (STEMI and NSTEMI, respectively) using an ECG. While patients with STEMI are urgently referred to a cath lab, patients with NSTEMI usually undergo a planned invasive coronary angiography (ICA) anywhere from 24-72 hours after arriving to the hospital. When an invasive coronary angiography can not explain the cause of a myocardial infarction, an MRI of the heart (a CMR) is often done as a follow-up investigation.\n\nA growing body of evidence suggests that performing a CMR before the planned ICA can provide an accurate diagnosis and defer the need for an ICA in many of these patients with NSTEMI.",[27,115],"Acute Coronary Syndrome",[117,118,119,120,121,122,123,115,60,124,125,126,127,128,129,130,131,132,133],"CMR","MRI","Cardiac MRI","Cardiac Magnetic Resonance","Cardiac Magnetic Resonance imaging","AMI","ACS","Non-STEMI","ICA","Invasive Coronary Angiography","Coronary Angiography","T1","T2","Magnetic Resonance Fingerprinting","Native T1","Native T2","Magnetic Resonance Angiography","2024-08-21",{"date":136,"type":32},"2024-08-22",{"date":138,"type":32},"2024-07-17",{"date":140,"type":20},"2025-12",{"name":142,"class":143},"Region Stockholm","OTHER_GOV",1,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":144},"100554137","european-survey-of-cardiovascular-disease-prevention-diabetes-and-chronic-kidney-disease-euroaspire-vi-100554137","NCT06495177","European Survey of Cardiovascular Disease Prevention, Diabetes and Chronic Kidney Disease (EUROASPIRE VI)","European Survey of Cardiovascular Disease Prevention, Diabetes and Chronic Kidney Disease","EUROASPIRE VI","Inclusion Criteria:\n\n* Patients having signed an informed Consent\n* Patients aged from 18 years old at the time of identification\n* At least six and at most 24 months elapsed between the index event (the recruiting diagnostic or treatment criteria below) and the date of interview\n* Patients meeting the recruiting diagnostic or treatment criteria:\n* Coronary patients: Acute coronary events (acute coronary syndrome {STEMI or NSTEMI}, unstable angina) or an emergency or elective revascularisation for coronary artery disease (CABG, PCI)\n* High cardiovascular disease (CVD) risk patients: patients free of CVD, who have been prescribed one or more of the following treatments: blood pressure and\u002For lipid-lowering and\u002For glucose lowering (diet and\u002For hypoglycaemic agents and\u002For insulin)\n\nExclusion Criteria:\n\n* Patients living outside defined geographical areas\n* Patients admitted to hospital from outside the geographical area or under the care of cardiologists in hospitals that do not participate in EUROASPIRE VI",{"count":154,"type":20},8000,"The goal of this observational study is to provide a unique European picture of preventive action by cardiologists, other specialists and primary care physicians looking after patients with coronary heart disease (CHD), individuals at high cardiovascular disease risk and all those with hypertension, dyslipidaemia (including familial hypercholesterolaemia), diabetes and dysglycaemia and chronic kidney disease (CKD) and determine whether the European guidelines on cardiovascular disease prevention, hypertension, lipids, diabetes and chronic kidney disease are being followed.",[157,115,158,26,27],"Coronary Disease","Unstable Angina","2024-07-02",{"date":161,"type":32},"2024-07-10",{"date":163,"type":32},"2024-06-07",{"date":165,"type":20},"2029-12",{"name":167,"class":168},"European Society of Cardiology","NETWORK",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":52,"phases":180,"briefSummary":181,"conditions":182,"keywords":184,"overallStatus":186,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":193,"locationsCount":195},"100484406","intensive-lipid-lowering-in-patients-with-stemi-and-nstemi-germany-on-target-100484406","NCT05587621","Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)","\"Intensive Lipid-Lowering Therapy Guided by a Cloud-based Software System (CLIMEDO GmbH) in Patients With ST-Elevation and Non-ST-Elevation Myocardial Infarctions\" (Germany on Target)","GoT","Inclusion Criteria:\n\n* patients with ST- and Non-ST-elevation myocardial infarctions\n\nExclusion Criteria:\n\n* patient without informed concent\n* patients in cardiogenic shock\n* patients with contraindication to lipid-lowering therapy\n* patients on lipid-lowering medications on admission","75 Years",{"count":179,"type":20},300,[54],"Intensive Lipid-Lowering Therapy guided by a cloud-based Software System (CLIMEDO GmbH) improves (European Society of Cardiolofgy\u002FEuropean Atherosclerosis Society) ESC\u002FEAS-guideline recommended LDL-cholesterol target attainment and adherence in patients with ST-Elevation Myocardial (STEMI) and Non-ST-Elevation Myocardial Infarctions (NSTEMI).",[26,27,183],"LDL-cholesterol",[185],"STEMI, NSTEMI; LDL-C; target attainment","NOT_YET_RECRUITING","2024-03-05",{"date":189,"type":32},"2024-03-07",{"date":191,"type":20},"2024-04-01",{"date":36,"type":20},{"name":194,"class":39},"Jena University Hospital",10,{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":203,"enrollmentInfo":204,"targetDuration":4,"studyType":52,"phases":206,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":144},"100456965","prospective-evaluation-of-complete-revascularization-in-patients-with-multivessel-disease-excluding-chronic-total-occlusions-100456965","NCT05230446","PRospective Evaluation of Complete Revascularization in Patients With multiveSsel Disease Excluding chroNic Total Occlusions","PRESENT","Inclusion Criteria:\n\n1. Age ≥ 18 years, ≤85 years\n2. The patient is an acceptable candidate for treatment with a drug eluting stent in accordance with the applicable guidelines on percutaneous coronary interventions, manufacturer's Instructions for Use and the Declaration of Helsinki\n3. Patient indication, lesion length and vessel diameter of the target lesion(s) are according to the 'Instructions for Use' that comes with every Resolute Onyx (Zotarolimus-Eluting stent) system.\n4. The patient is willing and able to cooperate with study procedures and required follow up visits\n5. The subject or legal representative has been informed of the nature of the study and agrees to its provisions and has provided an EC approved written informed consent, including data privacy authorization\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years and \\> 85 years.\n2. Single coronary vessel disease.\n3. No left anterior descending lesion.\n4. Patients in cardiogenic shock.\n5. Patients with STEMI.\n6. Presence of a chronic total occlusion (CTO) defined as coronary lesion with Thrombolysis in Myocardial Infarction (TIMI) flow grade 0 on initial angiography present for more than or equal to 3 months.\n7. Left main coronary artery disease\n8. Patients who cannot give informed consent or have a life expectancy of less than 12 months.\n9. Absolute contraindications or allergy that cannot be pre-medicated, to iodinated contrast or to any of the study medications, including both aspirin and P2Y12 inhibitors.\n10. Patients with an extreme LAD tortuosity imparing OCT catheter advancement\n11. Enrollment in another study with another investigational device or drug trial that has not reached the primary endpoint. The patient may only be enrolled once in the PRESENT study.\n12. Previous coronary artery bypass grafting (CABG).\n13. Patient requiring additional cardiac surgery within 6 months.\n14. Women of childbearing potential who do not have a negative pregnancy test result within 7 days before the procedure, women who are known to be pregnant, or who are breastfeeding.","85 Years",{"count":205,"type":20},609,[54],"This prospective, multicenter, non-randomized, single arm, objective performance goal (OPG) study is designed to evaluate clinical outcomes after complete revascularization by PCI and imaging guidance (OCT) in patients with multivessel coronary artery disease including left anterior descending (LAD) presenting with stable angina, or documented silent ischemia, or non-ST segment elevation acute coronary syndrome (NSTE-ACS).",[209,27,158,210,211,212,213],"Multi Vessel Coronary Artery Disease","Stable Angina","Coronary Artery Disease","Percutaneous Coronary Intervention","Optical Coherence Tomography","2022-01-25",{"date":216,"type":32},"2022-02-09",{"date":218,"type":32},"2021-11-18",{"date":220,"type":20},"2027-11-18",{"name":222,"class":39},"Erasmus Medical Center","Non-ST-Elevation Myocardial Infarction"]